FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280565730> ?p ?o ?g. }

• W4280565730 endingPage "103579" @default.
• W4280565730 startingPage "103579" @default.
• W4280565730 abstract "Objective(s): To evaluate the incidence, severity, and outcomes of coronavirus disease (COVID-19) and to identify demographic and clinical risk factors in patients with multiple sclerosis (MS).Material(s) and Method(s): A cross-sectional hospital records-based study was conducted on MS patients from clinics in Oman, Kuwait, and the United Arab Emirates (UAE) between March 2020 and February 2021. Patients diagnosed with MS using the 2010 McDonald criteria or previously accepted diagnostic criteria and with a positive diagnosis of COVID-19 were included in the study. Association between patient demographics, disease characteristics, use of disease-modifying therapies, and outcome of COVID-19 illness was evaluated statistically using an odds ratio estimation.Result(s): A total of 134 MS patients with COVID-19 (overall incidence rate of 3.7%) were analyzed in the study (116 with relapsing-remitting MS [RRMS], 11 with progressive MS; and 7 with clinically isolated MS). The median age of patients was 35.5 years. Of the total cohort, 127 (94.8%) patients were on disease-modifying therapy (DMT). A majority of the patients (126 [94.0%]) had mild COVID 19 illness and 122 (91.0%) made a full recovery while 1 (0.7%) patient died. A total of 8 patients (6.0%) were hospitalized; 3 (2.2%) required intensive care, while 2 (1.5%) reported ventilator requirement. The mean EDSS scores reported in the study were low (1.74) with 127 (94.8%) reporting a score between 0 – 4.5. Univariate logistic regression analysis identified a high EDSS score and progressive MS disease as a risk factor for moderate to severe COVID-19 requiring hospitalization. Rituximab use and anti CD20 therapy were also associated with a statistically significant higher risk of developing moderate/severe COVID-19. The presence of comorbidities was associated with a higher risk of non-recovery from the viral infection in both univariate and multivariate analyses.Conclusion(s): COVID-19 showed an incidence rate of 3.7% in the studied cohort of MS patients. The disease course and outcomes were mostly favorable with most patients not requiring hospitalization. A higher EDSS score, progressive disease, use of rituximab, and use of antiCD20 therapy were associated with statistically significant increased risk of developing moderate/severe COVID-19, while the presence of comorbidities was associated with a higher risk of non-recovery from COVID-19. Age, sex, smoking history, and duration of MS were not independent risk factors for increased severity or adverse COVID-19 disease outcomes. Objective(s): To evaluate the incidence, severity, and outcomes of coronavirus disease (COVID-19) and to identify demographic and clinical risk factors in patients with multiple sclerosis (MS). Material(s) and Method(s): A cross-sectional hospital records-based study was conducted on MS patients from clinics in Oman, Kuwait, and the United Arab Emirates (UAE) between March 2020 and February 2021. Patients diagnosed with MS using the 2010 McDonald criteria or previously accepted diagnostic criteria and with a positive diagnosis of COVID-19 were included in the study. Association between patient demographics, disease characteristics, use of disease-modifying therapies, and outcome of COVID-19 illness was evaluated statistically using an odds ratio estimation. Result(s): A total of 134 MS patients with COVID-19 (overall incidence rate of 3.7%) were analyzed in the study (116 with relapsing-remitting MS [RRMS], 11 with progressive MS; and 7 with clinically isolated MS). The median age of patients was 35.5 years. Of the total cohort, 127 (94.8%) patients were on disease-modifying therapy (DMT). A majority of the patients (126 [94.0%]) had mild COVID 19 illness and 122 (91.0%) made a full recovery while 1 (0.7%) patient died. A total of 8 patients (6.0%) were hospitalized; 3 (2.2%) required intensive care, while 2 (1.5%) reported ventilator requirement. The mean EDSS scores reported in the study were low (1.74) with 127 (94.8%) reporting a score between 0 – 4.5. Univariate logistic regression analysis identified a high EDSS score and progressive MS disease as a risk factor for moderate to severe COVID-19 requiring hospitalization. Rituximab use and anti CD20 therapy were also associated with a statistically significant higher risk of developing moderate/severe COVID-19. The presence of comorbidities was associated with a higher risk of non-recovery from the viral infection in both univariate and multivariate analyses. Conclusion(s): COVID-19 showed an incidence rate of 3.7% in the studied cohort of MS patients. The disease course and outcomes were mostly favorable with most patients not requiring hospitalization. A higher EDSS score, progressive disease, use of rituximab, and use of antiCD20 therapy were associated with statistically significant increased risk of developing moderate/severe COVID-19, while the presence of comorbidities was associated with a higher risk of non-recovery from COVID-19. Age, sex, smoking history, and duration of MS were not independent risk factors for increased severity or adverse COVID-19 disease outcomes." @default.
• W4280565730 created "2022-05-22" @default.
• W4280565730 creator A5000026859 @default.
• W4280565730 creator A5009941399 @default.
• W4280565730 creator A5041087554 @default.
• W4280565730 creator A5045037633 @default.
• W4280565730 creator A5046477954 @default.
• W4280565730 creator A5058188534 @default.
• W4280565730 creator A5065095387 @default.
• W4280565730 creator A5083472711 @default.
• W4280565730 date "2022-03-01" @default.
• W4280565730 modified "2023-09-27" @default.
• W4280565730 title "Incidence, Severity, Outcomes, and Risk Factors of COVID-19 in Multiple Sclerosis: An Observational Study in the Middle East" @default.
• W4280565730 doi "https://doi.org/10.1016/j.msard.2022.103579" @default.
• W4280565730 hasPublicationYear "2022" @default.
• W4280565730 type Work @default.
• W4280565730 citedByCount "0" @default.
• W4280565730 crossrefType "journal-article" @default.
• W4280565730 hasAuthorship W4280565730A5000026859 @default.
• W4280565730 hasAuthorship W4280565730A5009941399 @default.
• W4280565730 hasAuthorship W4280565730A5041087554 @default.
• W4280565730 hasAuthorship W4280565730A5045037633 @default.
• W4280565730 hasAuthorship W4280565730A5046477954 @default.
• W4280565730 hasAuthorship W4280565730A5058188534 @default.
• W4280565730 hasAuthorship W4280565730A5065095387 @default.
• W4280565730 hasAuthorship W4280565730A5083472711 @default.
• W4280565730 hasBestOaLocation W42805657301 @default.
• W4280565730 hasConcept C120665830 @default.
• W4280565730 hasConcept C121332964 @default.
• W4280565730 hasConcept C126322002 @default.
• W4280565730 hasConcept C144301174 @default.
• W4280565730 hasConcept C151956035 @default.
• W4280565730 hasConcept C156957248 @default.
• W4280565730 hasConcept C187212893 @default.
• W4280565730 hasConcept C187382586 @default.
• W4280565730 hasConcept C203014093 @default.
• W4280565730 hasConcept C2779134260 @default.
• W4280565730 hasConcept C2780640218 @default.
• W4280565730 hasConcept C3008058167 @default.
• W4280565730 hasConcept C38180746 @default.
• W4280565730 hasConcept C524204448 @default.
• W4280565730 hasConcept C61511704 @default.
• W4280565730 hasConcept C71924100 @default.
• W4280565730 hasConcept C72563966 @default.
• W4280565730 hasConceptScore W4280565730C120665830 @default.
• W4280565730 hasConceptScore W4280565730C121332964 @default.
• W4280565730 hasConceptScore W4280565730C126322002 @default.
• W4280565730 hasConceptScore W4280565730C144301174 @default.
• W4280565730 hasConceptScore W4280565730C151956035 @default.
• W4280565730 hasConceptScore W4280565730C156957248 @default.
• W4280565730 hasConceptScore W4280565730C187212893 @default.
• W4280565730 hasConceptScore W4280565730C187382586 @default.
• W4280565730 hasConceptScore W4280565730C203014093 @default.
• W4280565730 hasConceptScore W4280565730C2779134260 @default.
• W4280565730 hasConceptScore W4280565730C2780640218 @default.
• W4280565730 hasConceptScore W4280565730C3008058167 @default.
• W4280565730 hasConceptScore W4280565730C38180746 @default.
• W4280565730 hasConceptScore W4280565730C524204448 @default.
• W4280565730 hasConceptScore W4280565730C61511704 @default.
• W4280565730 hasConceptScore W4280565730C71924100 @default.
• W4280565730 hasConceptScore W4280565730C72563966 @default.
• W4280565730 hasLocation W42805657301 @default.
• W4280565730 hasLocation W42805657302 @default.
• W4280565730 hasOpenAccess W4280565730 @default.
• W4280565730 hasPrimaryLocation W42805657301 @default.
• W4280565730 hasRelatedWork W2047242939 @default.
• W4280565730 hasRelatedWork W2098992779 @default.
• W4280565730 hasRelatedWork W2102575453 @default.
• W4280565730 hasRelatedWork W2167082840 @default.
• W4280565730 hasRelatedWork W2334446993 @default.
• W4280565730 hasRelatedWork W2415280530 @default.
• W4280565730 hasRelatedWork W2785135794 @default.
• W4280565730 hasRelatedWork W2889812457 @default.
• W4280565730 hasRelatedWork W2948012060 @default.
• W4280565730 hasRelatedWork W2997255441 @default.
• W4280565730 hasVolume "59" @default.
• W4280565730 isParatext "false" @default.
• W4280565730 isRetracted "false" @default.
• W4280565730 workType "article" @default.